New drug combo aims to stop HPV head and neck cancer recurrence

This study tests whether adding fianlimab to the immunotherapy cemiplimab works better than cemiplimab alone at preventing cancer return in people with HPV-positive head and neck cancer who have signs of leftover cancer after initial treatment. About 68 adults will receive either the combination or cemiplimab alone and be monitored for recurrence and side effects. The goal is to improve recurrence-free survival.